ATE208208T1 - Halogenid-enthaltende insulinzubereitungen - Google Patents

Halogenid-enthaltende insulinzubereitungen

Info

Publication number: ATE208208T1
Authority: AT; Austria
Prior art keywords: halogenides; insulin preparations; preparations containing; insulin; halogenide
Prior art date: 1996-06-20

Application number

AT97928123T

Other languages

English (en)

Inventor

Elsebeth Norup

Liselotte Langkjaer

Svend Havelund

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-20

Filing date

1997-06-19

Publication date

2001-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE208208(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-19 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2001-11-15 Application granted granted Critical

2001-11-15 Publication of ATE208208T1 publication Critical patent/ATE208208T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title abstract 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT97928123T 1996-06-20 1997-06-19 Halogenid-enthaltende insulinzubereitungen ATE208208T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK68596		1996-06-20
PCT/DK1997/000268 WO1997048414A1 (en)	1996-06-20	1997-06-19	INSULIN PREPARATIONS CONTAINING NaCl

Publications (1)

Publication Number	Publication Date
ATE208208T1 true ATE208208T1 (de)	2001-11-15

Family

ID=8096378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97928123T ATE208208T1 (de)	1996-06-20	1997-06-19	Halogenid-enthaltende insulinzubereitungen

Country Status (21)

Country	Link
EP (1)	EP0921812B2 (de)
JP (2)	JP4404380B2 (de)
KR (1)	KR100451778B1 (de)
CN (1)	CN1120019C (de)
AT (1)	ATE208208T1 (de)
AU (1)	AU720484B2 (de)
BR (1)	BR9709845B1 (de)
CA (1)	CA2258097C (de)
CZ (1)	CZ297937B6 (de)
DE (1)	DE69708121T3 (de)
DK (1)	DK0921812T4 (de)
ES (1)	ES2167751T5 (de)
HU (1)	HU228094B1 (de)
IL (2)	IL127366A0 (de)
NO (1)	NO324430B1 (de)
PL (1)	PL189964B1 (de)
PT (1)	PT921812E (de)
RU (1)	RU2182015C2 (de)
UA (1)	UA49890C2 (de)
WO (1)	WO1997048414A1 (de)
ZA (1)	ZA975470B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69924232D1 (de)	1998-01-09	2005-04-21	Novo Nordisk As	Stabilisierte insulin-zubereitungen
EP1131089B1 (de) *	1998-11-18	2004-02-18	Novo Nordisk A/S	Stabile wässrige insulinzubereitungen ohne phenol und kresol
US6489292B1 (en)	1998-11-18	2002-12-03	Novo Nordisk A/S	Stable aqueous insulin preparations without phenol and cresol
PT1146896E (pt) *	1999-01-26	2002-10-31	Lilly Co Eli	Formulacoes monodispersas de analogo acilado e hexamerico insulina
EP1165063A1 (de) *	1999-04-05	2002-01-02	Verteletsky, Pavel Vasilievich	Verwendung von bernsteinsäure und dessen salzen zur behandlung von diabetes und wundheilung
EP1523993A1 (de) *	1999-12-16	2005-04-20	Eli Lilly & Company	Polypeptidzusammensetzungen mit verbesserter Stabilität
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
DE60018105T2 (de) *	1999-12-16	2005-12-29	Eli Lilly And Co., Indianapolis	Polypeptidzusammensetzungen mit verbesserter stabilität
AU2005291233B2 (en)	2004-10-05	2011-02-03	Novo Nordisk A/S	A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
RU2288000C1 (ru) *	2005-04-27	2006-11-27	Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН)	Раствор инсулина для перорального введения
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR112015013223A2 (pt) *	2012-12-26	2017-07-11	Wockhardt Ltd	composição farmacêutica
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
JP2020143105A (ja) *	2014-01-09	2020-09-10	サノフイＳａｎｏｆｉ	インスリンアスパルトの安定化された医薬製剤
EP3091965A1 (de)	2014-01-09	2016-11-16	Sanofi	Stabilisierte glycerinfreie pharmazeutische formulierungen von insulinanaloga und/oder insulinderivaten
SG11201604706TA (en) *	2014-01-09	2016-07-28	Sanofi Sa	Stabilized pharmaceutical formulations of insulin aspart
JP2020114861A (ja) *	2014-01-09	2020-07-30	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
CN112957455A (zh)	2014-01-09	2021-06-15	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
SG11202111312UA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
AU2021379990A1 (en) *	2020-11-16	2023-06-29	W. L. Gore & Associates, Inc.	Formulations, methods, and pre-filled multi-dose injection devices without cloud point

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK116527B (da) *	1967-03-01	1970-01-19	Nordisk Insulinlab	Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
SU1528496A1 (ru) *	1972-10-17	1989-12-15	Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии	Дегидратирующее средство
US4783441A (en) †	1979-04-30	1988-11-08	Hoechst Aktiengesellschaft	Aqueous protein solutions stable to denaturation
US4439181A (en) *	1981-01-26	1984-03-27	Regents Of The University Of Minnesota	Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) †	1981-03-10	1986-02-27	Novo Nordisk A/S	Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) *	1984-05-29	1989-06-13	Eli Lilly And Company	Stabilized insulin formulations
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
PT93057B (pt) *	1989-02-09	1995-12-29	Lilly Co Eli	Processo para a preparacao de analogos da insulina
DE122006000015I1 (de) *	1993-06-21	2006-06-29	Novo Nordisk As	Asp-B28-Insulinkristalle
SI0792290T1 (en) *	1993-09-17	2001-12-31	Novo Nordisk As	Acylated insulin
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations

1997
- 1997-06-19 DK DK97928123.5T patent/DK0921812T4/da active
- 1997-06-19 HU HU9904031A patent/HU228094B1/hu unknown
- 1997-06-19 BR BRPI9709845-0A patent/BR9709845B1/pt not_active IP Right Cessation
- 1997-06-19 UA UA98126686A patent/UA49890C2/uk unknown
- 1997-06-19 RU RU99101068/14A patent/RU2182015C2/ru active
- 1997-06-19 AT AT97928123T patent/ATE208208T1/de active
- 1997-06-19 PT PT97928123T patent/PT921812E/pt unknown
- 1997-06-19 CZ CZ0395698A patent/CZ297937B6/cs not_active IP Right Cessation
- 1997-06-19 PL PL97330763A patent/PL189964B1/pl unknown
- 1997-06-19 CA CA2258097A patent/CA2258097C/en not_active Expired - Lifetime
- 1997-06-19 JP JP50212998A patent/JP4404380B2/ja not_active Expired - Lifetime
- 1997-06-19 IL IL12736697A patent/IL127366A0/xx active IP Right Grant
- 1997-06-19 ES ES97928123T patent/ES2167751T5/es not_active Expired - Lifetime
- 1997-06-19 AU AU32536/97A patent/AU720484B2/en not_active Expired
- 1997-06-19 DE DE69708121T patent/DE69708121T3/de not_active Expired - Lifetime
- 1997-06-19 KR KR10-1998-0710429A patent/KR100451778B1/ko not_active Expired - Lifetime
- 1997-06-19 WO PCT/DK1997/000268 patent/WO1997048414A1/en not_active Ceased
- 1997-06-19 EP EP97928123A patent/EP0921812B2/de not_active Expired - Lifetime
- 1997-06-19 CN CN97195648A patent/CN1120019C/zh not_active Expired - Lifetime
- 1997-06-20 ZA ZA9705470A patent/ZA975470B/xx unknown
1998
- 1998-12-02 IL IL127366A patent/IL127366A/en not_active IP Right Cessation
- 1998-12-18 NO NO19985981A patent/NO324430B1/no not_active IP Right Cessation
2009
- 2009-05-07 JP JP2009112970A patent/JP2009235075A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CZ297937B6 (cs)	2007-05-02
CZ395698A3 (cs)	1999-05-12
UA49890C2 (uk)	2002-10-15
NO985981L (no)	1998-12-18
BR9709845B1 (pt)	2008-11-18
CN1120019C (zh)	2003-09-03
EP0921812B1 (de)	2001-11-07
KR100451778B1 (ko)	2004-11-16
JP4404380B2 (ja)	2010-01-27
DK0921812T4 (da)	2012-04-02
ES2167751T3 (es)	2002-05-16
JP2009235075A (ja)	2009-10-15
WO1997048414A1 (en)	1997-12-24
HUP9904031A2 (hu)	2000-04-28
NO985981D0 (no)	1998-12-18
HUP9904031A3 (en)	2000-10-30
IL127366A (en)	2007-07-04
KR20000022031A (ko)	2000-04-25
HU228094B1 (en)	2012-10-29
PL189964B1 (pl)	2005-10-31
PT921812E (pt)	2002-04-29
ES2167751T5 (es)	2012-03-30
BR9709845A (pt)	1999-08-10
AU720484B2 (en)	2000-06-01
EP0921812A1 (de)	1999-06-16
CA2258097C (en)	2011-02-08
IL127366A0 (en)	1999-10-28
AU3253697A (en)	1998-01-07
EP0921812B2 (de)	2011-12-21
CN1222083A (zh)	1999-07-07
PL330763A1 (en)	1999-05-24
ZA975470B (en)	1997-12-22
DK0921812T3 (da)	2002-02-11
RU2182015C2 (ru)	2002-05-10
DE69708121D1 (de)	2001-12-13
DE69708121T2 (de)	2002-08-01
NO324430B1 (no)	2007-10-15
JP2000513344A (ja)	2000-10-10
CA2258097A1 (en)	1997-12-24
DE69708121T3 (de)	2012-05-16

Legal Events

Date	Code	Title	Description
2002-02-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
DE69708121D1 (de)	2001-12-13	Halogenid-enthaltende insulinzubereitungen
DK0428038T3 (da)	1994-08-29	Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DK0812198T3 (da)	2002-03-18	Stabilisering af prostaglandinpræparater
ATE275940T1 (de)	2004-10-15	Medizinische aerosolformulierungen von formoterol
DE69729786D1 (de)	2004-08-12	Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DE68924540D1 (de)	1995-11-16	Medizinische Aerosolformulierungen.
FI19992420L (fi)	1999-11-10	Mikrobifytaasin kloonaus ja ilmentäminen
DE69715482D1 (de)	2002-10-24	Herstellung von 1,1,1,3,3-Pentachlorbutan und von 1,1,1,3,3-Pentafluorbutan
DE69417252D1 (de)	1999-04-22	Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
ATE218581T1 (de)	2002-06-15	Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
NO20012249L (no)	1998-12-16	Faststoffsammensetning inneholdende D-mannitol og cerivastatin samt anvendelse av faststoffsammensetning forfremstilling av farmasöytisk preparat
DE59708905D1 (de)	2003-01-16	Injektionsformulierungen von avermectinen und milbemycinen
FI906328A0 (fi)	1990-12-20	En anordning foer kontrollerad administrering av aktiva aemnen i ett funktionerande medium.
ATE92542T1 (de)	1993-08-15	Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor\|than.
BR9707657A (pt)	1999-07-27	Benzotiofenos formulações contendo os mesmos e métodos
NO922136L (no)	1992-05-29	Anvendelse av gibberelliner for behandling av prostatitisog psoriasis
ES2152315T3 (es)	2001-02-01	Xamoneline tartrato.
DE59101818D1 (de)	1994-07-14	Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
DE69401030D1 (de)	1997-01-16	Aerosolformulierung enthaltend Fusafungin
FR2696926B1 (fr)	1994-12-09	Prothèse totale du genou du type intracondylienne.
ATE204286T1 (de)	2001-09-15	Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
DK0730861T3 (da)	2000-10-09	Anvendelse af 6,7-substituerede 2-aminotetraliner til fremstilling af farmaceutiske præparater, der er nyttige til behandli
FR2707492B1 (fr)	1995-08-25	Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application.
FI954401A7 (fi)	1995-09-18	Atseotrooppimaiset koostumukset, joissa on 1,1,1,2,3,3,3-heptafluoripr opaania ja 1,1-difluorietaania
ATE80143T1 (de)	1992-09-15	Isomere formyl-trimethylbicyclo(2,2,2)oct-7-ene.